Helping you shape your future

Strategic inshights, creative and practical recommendations, horizon scannig for emerging trends.

Case studies

Partnership with client’s Asia-Pacific team on regional activity and evidence roadmaps

Read more >

Framework to assess the early commercial and market access potential of an asset

Read more >

Assessment framework of access landscape, reimbursement, and development plan for early pipeline assets

Read more >

Co-creation of a value assessment framework for early assets in the Asia-Pacific region​

Read more >

Up to 30% of global HTA template requirements may not be met by a traditional GVD

Read more >

Emerging biomarker in a hemato-oncology indication

Read more >

Understanding the impact of the ESMO value framework and its revisions to existing and pipeline oncology assets

Read more >

Market access roadmap in hemophilia B

Read more >

Proactively managing HTA challenges for follow-on indications in an orphan disease

Read more >

Healthcheck assessment for novel asset in moderate to severe rheumatoid arthritis

Read more >

This top-5 pharma company chose the PRMA Navigator® to accelerate the generation of simultaneous HTA submissions and achieve up to 80% auto-population of their first drafts

Read more >

Estimating the eligible patient population for a targeted oncology therapy

Read more >

Development of a value story, GVD, and payer materials

Read more >

Developing an economic model to optimize market access opportunities

Read more >

Developing an international market access strategy to optimize pricing and reimbursement opportunities

Read more >

Critically evaluating pricing and access risks and opportunities for an asset under different clinical development scenarios

Read more >

Maximize the pricing and market access potential of your early pipeline

Read more >

Developing a market access and HEOR roadmap in a rapidly evolving landscape

Read more >

Creating compelling real-world evidence that supports favorable HTA

Read more >

Improving pharmaceutical portfolio management and decision-making for early assets

Read more >

Evidence synthesis and development of economic models

Read more >

Combinations: P&R considerations

Read more >

Improve health technology assessment submissions

Read more >

Demonstrating value using a new approach to economic modeling

Read more >

Blocking competitor intrusion in competitive pharmaceutical markets

Read more >

Top-5 pharma discovers a new way to evaluate pricing opportunities

Read more >

Identifying critical risks for payer decision-making

Read more >

Anticipate evidence needs early on and accelerate development of focused evidence generation activities

Read more >

Assessing evidence generation strategies for an asset with a novel biomarker in a rapidly evolving landscape

Read more >

Achieving a positive HTA outcome with insight from payer and clinician advisory boards

Read more >

Bolstering payer discussions to solve persistent challenges

Read more >

Strategic roadmap for optimized global market access for CAR-T

Read more >

Accelerating decision-making for international market access

Read more >

Landscape assessments and market access strategy for CDx-drug pairings

Read more >

Strategic projects to inform commercialization decisions in RSV

Read more >

Strategic and tactical support achieves HTA success

Read more >

Recommendations for an ophthalmology launch plan in the EU

Read more >

Using payer perspectives to inform evidence generation strategies for successful market access

Read more >

Digitally transforming health technology assessment (HTA) submission processes

Read more >

Value frameworks scoring of a new oncology treatment and comparators

Read more >

Publications

Articles

Market access in Asia-Pacific: key challenges for manufacturers

Read more >

Take your market access to the next level: your free digital transformation eBook

Read more >

Meet our latest market access colleagues in Asia-Pacific

Read more >

Digital technology is transforming market access, but insight has a human heartbeat

Read more >

Transforming your market access in Asia-Pacific

Read more >

Driving market access readiness in the US through a unique digital application

Read more >

Cornerstones of ‘fair’ drug coverage: ICER and OHE release new white paper

Read more >

PM Society Digital Awards: market access award winner

Read more >

CMS releases its annual IPPS final rule: key updates for manufacturers

Read more >

PRMA Consulting announces its new office opening in Singapore

Read more >

How will Covid-19 shape the evidence assessed by payers and HTA decision-makers?

Read more >

PRMA Healthcheck® for assets in early stages of clinical development

Read more >

Why understanding payer archetypes is key to US market access

Read more >

Digital transformation in market access: don’t get lost in translation

Read more >

Completing the puzzle: market access in Asia-Pacific

Read more >

Preparing for ICER assessments: key recommendations for manufacturers

Read more >

Why on-demand insight is key to successful payer submissions

Read more >

ICER 2020 value assessment framework: 7 updates that market access professionals need to understand

Read more >

Digital transformation: shaping the future of market access

Read more >

How collaboration and connectivity can accelerate payer submissions and drive faster patient access

Read more >

Breaking boundaries in market access: PRMA Consulting annual company meeting 2020

Read more >

WEConnect: Connecting Women’s Enterprises with Global Opportunities

Read more >

Payer and HTA submissions: how digital technology is transforming market access processes

Read more >

Reducing market access risk: how digital technology is strengthening strategies

Read more >

Wherever we work, we work together

Read more >

Home working: 6 tips for fostering team connectivity in times of distance and disruption

Read more >

COVID-19: how your market access can fly even when you are grounded

Read more >

Wellbeing at PRMA Consulting

Read more >

Payer insight: 5 ways to get the most from your advisor interactions

Read more >

PRMA Consulting expands its US presence

Read more >

Driving market access success in the US

Read more >

How a leading pharma company gained significant market access insights prior to launch

Read more >

How to drive payer submission readiness for your late-phase products

Read more >

Digitization in primary research: a smart addition to traditional market access research methods

Read more >

The things you need to know about the digital transformation of primary research

Read more >

Are you in touch with the latest payer thinking?

Read more >

Transforming value and access outcomes in the Asia-Pacific region

Read more >

The influence of the patient voice in regulatory and health technology assessment activities

Read more >

How to identify the potential for commercial success in early-stage product development

Read more >

Managed entry agreements: learnings for successful development from a UK perspective

Read more >

Managed entry agreements: theory and principals

Read more >

Payer insight: 5 ways to get the most from your advisor interactions

Read more >

Finalist in the HealthEconomics.com’s 1st Annual HEOR and RWE Innovation Webinar Series: the PRMA Navigator®

Read more >

The Fierce Innovation Award identifying outstanding innovation in Life Sciences

Read more >

61st ASH Annual Meeting and Exposition

Read more >

Digital innovation empowers global teams and local affiliates to shorten the time to market access

Read more >

Toby Gosden joins PRMA Consulting

Read more >

Nathan White joins PRMA Consulting

Read more >

Mapping patient involvement in NICE appraisals of oncology products

Read more >

Watch and vote in the 2019 Health Economics Innovation Series

Read more >

Do market access withdrawals impact patient access to treatment in Germany?

Read more >

Orphan drug re-assessments in Germany: the impact on additional benefit and price

Read more >

Do your global value dossiers contain these 5 common omissions?

Read more >

How digital technology is transforming market access in the Asia-Pacific region

Read more >

ISPOR Europe 2019

Read more >

Free eBook: how to accelerate the generation of simultaneous, high-quality HTA submissions

Read more >

Overcoming the market access challenges associated with high-cost combination therapies

Read more >

Championing digital transformation within biotech and pharma companies

Read more >

Pricing and reimbursement in Canada: a market access update

Read more >

Exploring the challenges for pricing and reimbursement of high-cost combination therapies

Read more >

Potential solutions for pricing and reimbursement of high-cost combination products

Read more >

The relevance of patient perspectives to value

Read more >

Incorporating the patient voice in market access

Read more >

Pricing and reimbursement of CAR‐T in Germany

Read more >

Managed entry agreements: regional and national insight

Read more >

Measuring survival benefit in oncology health technology assessments

Read more >

Exploring the benefits of cloud computing for market access.

Read more >

Protecting your market access data. 10 questions to ask your suppliers

Read more >

Protect your market access data: the value of ISO27001

Read more >

Four recommendations to kick-start the digital transformation of your market access processes

Read more >

Exploring the challenges for pricing and reimbursement of high-cost combination therapies

Read more >

Managed entry agreements: regional and national insight

Read more >

Five strategies for CAR-T pricing and reimbursement success

Read more >

Review of CAR-T assessments and implications for novel agents

Read more >

Recommendations for successfully developing managed entry agreements

Read more >

Designing effective managed entry agreements: insight from Spain

Read more >

Patient-centricity: a crucial approach for market access?

Read more >

Biosimilars: market access considerations

Read more >

Exploring the challenges for pricing and reimbursement of high-cost combination therapies

Read more >

Transforming the market access landscape: the role of digital applications

Read more >

Evaluate how digital technology can better enable processes and requirements

Read more >

PRMA Consulting Expert Advisory Group on Complex Pricing (EAGCP): Focus on gene therapies

Read more >

Achieving a variable price by indication: free eBook download

Read more >

Indication-based pricing: your free eBook download

Read more >

What is market access?

Read more >